Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
Tofacitinib citrate is the pharmaceutical-grade citrate salt of tofacitinib, a Janus kinase (JAK) inhibitor. It is synthesized via controlled acid-base reaction and crystallization. Molecular Formula: C16H25N8O7P; CAS No.: 1098436-77-3.
Contraindicated in patients with severe hepatic impairment or active infections. Requires strict storage at 2-8°C in moisture-proof containers. Handling mandates PPE to prevent dermal exposure.